natgillin/translations-raw huggingface dataset:
Simparica can be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites). 
Zdravilo Simparica se lahko uporablja kot del zdravljenja alergijskega dermatitisa, ki ga povzročajo bolhe (alergijske reakcije na ugrize bolh).
The active substance in Simparica, sarolaner acts as an ‘ectoparasiticide'. 
Zdravilna učinkovina v zdravilu Simparica, sarolaner, deluje kot ektoparaziticid.
Another study involved dogs infested with sarcoptic mange. 
Opravljena je bila tudi študija, ki je vključevala pse z garjami vrste Sarcoptes scabiei.
For Simparica the percentage of dogs with no live ear mites present was 91% at day 30 increasing to 99% on day 60, following two treatments. 
Pri zdravljenju z zdravilom Simparica je bil delež psov, pri katerih na 30. dan po zdravljenju ni bilo več prisotnih živih ušesnih garjavcev, 91 %, ki je na 60. dan, tj. po dveh zdravljenjih, narastel na 99 %.
Simparica is a veterinary medicine used to treat infestations with ticks and fleas, demodectic and sarcoptic mange (skin infestations caused by two different types of mites) and ear mite infestations in dogs. 
Zdravilo Simparica je zdravilo za uporabo v veterinarski medicini, ki je namenjeno zdravljenju infestacij s klopi in bolhami, garjavci vrste Demodex canis in Sarcoptes scabiei (kožne garjavosti, ki jo povzročata dve vrsti garjavcev) ter infestacij z ušesnimi garjavci pri psih.
For treatment of tick and flea infestations Simparica should be given once every month throughout the flea and/or tick season for optimal control. 
Za zdravljenje infestacij s klopi in bolhami se zdravilo Simparica v sezoni klopov in/ali bolh daje enkrat mesečno, da bi dosegli optimalen nadzor.
How does Simparica work? 
Kako zdravilo Simparica deluje?
Simparica was as effective as moxidectin/imidacloprid. 
Zdravilo Simparica je bilo enako učinkovito kot moksidektin/imidakloprid.
In a study with 98 dogs with demodectic mange, 63 dogs were treated with Simparica monthly for up to six months and 35 dogs received moxidectin/imidacloprid. 
V študiji, ki je zajela 98 psov z garjavci vrste Demodex canis, je bilo 63 psov zdravljenih enkrat na mesec z zdravilom Simparica v obdobju do šestih mesecev, medtem ko je 35 psov prejemalo moksidektin/imidakloprid.
53 dogs were treated with Simparica for two months whilst 26 dogs were given a medicine containing moxidectin and imidacloprid. 
53 psov je dva meseca prejemalo zdravilo Simparica, 26 psov pa zdravilo, ki je vsebovalo moksidektin in imidakloprid.
189 dogs were treated with Simparica for three months whilst 96 dogs were given another medicine, spinosad. 
189 psov je tri mesece prejemalo zdravilo Simparica, 96 psov pa drugo zdravilo, spinosad.
Safety information has been included in the summary of product characteristics and the package leaflet for Simparica, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers. 
V povzetek glavnih značilnosti zdravila Simparica in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
In a study involving dogs with ear mite infestation, 283 dogs were treated with Simparica and 131 dogs received moxidectin/imidacloprid (a spot-on mite treatment). 
V študiji, ki je zajela pse z infestacijami ušesnih garjavcev, je bilo 283 psov zdravljenih z zdravilom Simparica, 131 psov pa je prejemalo moksidektin/imidakloprid (zdravilo proti garjam za kožni nanos).
After Simparica is given its activity against ticks and fleas lasts for at least 5 weeks. 
Po dajanju zdravila Simparica učinek proti klopom in bolham traja najmanj pet tednov.
For treatment of sarcoptic mange, Simparica is given monthly for two consecutive months. 
Za zdravljenje infestacij z garjami vrste Sarcoptes scabiei se zdravilo Simparica daje enkrat na mesec dva meseca zapored.
How is Simparica used? 
Kako se zdravilo Simparica uporablja?
Simparica was as effective as fipronil in reducing tick counts for up to 90 days after treatment. 
Zdravilo Simparica je bilo enako učinkovito pri zmanjševanju števila klopov kot zdravilo fipronil, kar je trajalo do 90 dni po zdravljenju.
For more information about treatment with Simparica, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za več informacij o zdravljenju z zdravilom Simparica naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For practical information about using Simparica, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za praktične informacije o uporabi zdravila Simparica naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
Dogs with live mites on day 30 after initial treatment received a second treatment. 
Psom, ki so imeli na 30. dan po prejetem zdravilu na koži žive garjavce, so zdravilo dali še enkrat.
Simparica was as effective as spinosad in reducing flea counts for up to 90 days after treatment. 
Zdravilo Simparica je bilo enako učinkovito pri zmanjševanju števila bolh kot zdravilo spinosad, kar je trajalo do 90 dni po zdravljenju.
The appropriate strength tablet(s) should be used according to the dog's weight. 
Ustrezna jakost tablete oziroma tablet se določi glede na telesno maso psa.
Simparica was as effective as moxidectin and imidacloprid in eliminating live mites in skin scrapings. 
Zdravilo Simparica je bilo pri odpravljanju živih garjavcev v kožnih ostružkih enako učinkovito kot moksidektin in imidakloprid.
122 dogs were treated with Simparica for three months whilst 59 dogs were treated with another medicine, fipronil, against ticks. 
122 psov je proti klopom tri mesece prejemalo zdravilo Simparica, 59 psov pa drugo zdravilo, fipronil.
For treatment of demodectic mange Simparica should be given once a month for at least three months. 
Za zdravljenje infestacij z garjami vrste Demodex canis se zdravilo Simparica daje enkrat na mesec najmanj tri mesece zapored.
In order to be exposed to the active substance, fleas and ticks must attach to the skin and commence feeding on the dog's blood. 
Da bi bili bolhe in klopi izpostavljeni zdravilni učinkovini, se morajo pritrditi na kožo in se začeti hraniti s krvjo psa. Sarolaner ubije zajedavce, ki so zaužili kri psa, tako da deluje na njihov živčni sistem.
The risk of excess iron build-up was considered limited but should be followed up after approval. 
Tveganje za kopičenje presežka železa je bilo ocenjeno kot majhno, vendar ga je treba po odobritvi spremljati.
The tablets must be chewed and not swallowed whole. 
Tablete je treba prežvečiti in se jih ne sme pogoltniti celih.
The European Commission granted a marketing authorisation valid throughout the European Union for Velphoro on 26 August 2014. 
Evropska komisija je dovoljenje za promet z zdravilom Velphoro, veljavno po vsej Evropski uniji, izdala 26. avgusta 2014.
There were no major safety concerns and although tolerability is slightly lower than with sevelamer, the overall safety profile was acceptable. 
Večjih pomislekov glede varnosti ni bilo in čeprav bolniki zdravilo nekoliko slabše prenašajo kot sevelamer, je splošni varnostni profil sprejemljiv.
The full EPAR and risk management plan summary for Velphoro can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Velphoro sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Velphoro's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Velphoro večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Patients with severe kidney disease cannot eliminate phosphate from their bodies. 
Bolniki s hudo boleznijo ledvic ne morejo izločiti fosfatov iz telesa.
The dose of Velphoro should be adjusted every two to four weeks, until an acceptable level of phosphate in the blood is reached, which should then be monitored regularly. 
Odmerek zdravila Velphoro je treba prilagoditi vsaka dva do štiri tedne, dokler niso dosežene sprejemljive ravni fosfatov v krvi, ki jih je nato treba redno spremljati.
What measures are being taken to ensure the safe and effective use of Velphoro? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Velphoro?
This is a summary of the European public assessment report (EPAR) for Velphoro. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Velphoro.
Other information about Velphoro 
Druge informacije o zdravilu Velphoro
The study looked at the change in the amount of phosphate in the blood, measured in units of mmol/L. 
V študiji so proučevali spremembo količine fosfatov v krvi, ki so jo merili v enotah mmol/l.
After 3 months of treatment, blood-phosphate levels fell on average by 0.7 mmol/L with Velphoro compared with 0.8 mmol/L with sevelamer, and after 6 months of treatment 53% of patients on Velphoro had normal blood-phosphate levels (1.13 to 1.78 mmol/L) compared with 54% of patients on sevelamer. 
Po 3 mesecih zdravljenja so se ravni fosfatov v krvi v povprečju znižale za 0,7 mmol/l pri uporabi zdravila Velphoro in za 0,8 mmol/l pri uporabi sevelamerja, po 6 mesecih zdravljenja pa so normalne ravni fosfatov v krvi (od 1,13 do 1,78 mmol/l) zabeležili pri 53 % bolnikov, ki so prejemali zdravilo Velphoro, in pri 54 % bolnikov, ki so prejemali sevelamer.
The recommended starting dose is 1,500 mg (3 tablets) a day, taken in divided doses together with meals. 
Priporočeni začetni odmerek je 1 500 mg (3 tablete) na dan, ki se jemlje v deljenih odmerkih ob obrokih.
This leads to hyperphosphataemia (high blood phosphate levels), which, in the long term, can cause complications such as heart and bone disease. 
Zaradi tega se pojavi hiperfosfatemija (visoke ravni fosfatov v krvi), ki lahko čez čas povzroči zaplete, kot so bolezni srca in kosti.
Velphoro is available as chewable tablets (containing 500 mg of iron). 
Zdravilo Velphoro je na voljo v obliki žvečljivih tablet (ki vsebujejo 500 mg železa).
A risk management plan has been developed to ensure that Velphoro is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Velphoro je bil pripravljen načrt obvladovanja tveganj.
After 6 months, more than half of the patients could then continue on the same treatment for up to one year, while a small group received Velphoro at a lower dose for three weeks only. 
Po 6 mesecih je lahko več kot polovica bolnikov še naprej prejemala enako zdravljenje do enega leta, manjša skupina pa je le tri tedne prejemala manjše odmerke zdravila Velphoro.
It is not intended to provide practical advice on how to use Velphoro. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The CHMP concluded that Velphoro showed a clear beneficial effect in lowering phosphate levels. 
Zaključil je tudi, da je zdravilo Velphoro izkazalo jasen koristen učinek na zniževanje ravni fosfatov.
For more information about treatment with Velphoro, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Velphoro preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Velphoro has been studied in one main study involving 1,059 adults with long-term kidney disease and hyperphosphataemia. 
Zdravilo Velphoro so proučili v eni glavni študiji, v kateri je sodelovalo 1 059 odraslih z dolgotrajno boleznijo ledvic ali hiperfosfatemijo.
What benefits of Velphoro have been shown in studies? 
Kakšne koristi je zdravilo Velphoro izkazalo v študijah?
In patients whose dose of Velphoro was then lowered, phosphate levels increased after 3 weeks, whereas the levels remained stable in those who continued treatment on the same dose for up to one year. 
Pri bolnikih, ki so jim nato zmanjšali odmerek zdravila Velphoro, so ravni fosfatov po 3 tednih narasle, medtem ko so pri tistih, ki so se še naprej zdravili z enakim odmerkom do enega leta, ostale nespremenjene.
When taken with meals, the iron contained in Velphoro attaches to phosphate from food within the gut, preventing it from being absorbed into the body and helping to keep down the phosphate levels in the blood. 
Ko se zdravilo Velphoro vzame ob obroku, se železo, ki ga vsebuje, v črevesju veže na fosfate iz hrane, s čimer prepreči, da bi jih telo absorbiralo, in tako pomaga ohranjati nizke ravni fosfatov v krvi.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Velphoro, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Velphoro in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Why is Velphoro approved? 
Zakaj je bilo zdravilo Velphoro odobreno?
The most common side effects with Velphoro (which may affect more than 1 in 10 people) are diarrhoea and discoloured faeces, which may become less frequent with continued treatment. 
Najpogostejša neželena učinka zdravila Velphoro (ki lahko prizadeneta več kot 1 osebo od 10) sta driska in sprememba barve blata, njuna pogostnost pa se lahko med neprekinjenim zdravljenjem zmanjša.
For the full list of all side effects and restrictions with Velphoro, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Velphoro glejte navodilo za uporabo.
What is Velphoro and what is it used for? 
Kaj je zdravilo Velphoro in za kaj se uporablja?
Velphoro is used with other treatments such as calcium or vitamin-D supplements which help to control bone disease linked to kidney failure and high phosphate levels. 
Zdravilo Velphoro se uporablja sočasno z drugimi zdravili, kot so dodatki kalcija ali vitamina D, ki pomagajo obvladovati bolezen kosti, povezano z odpovedjo ledvic in visokimi ravnmi fosfatov.
What are the risks associated with Velphoro? 
Kakšna tveganja so povezana z zdravilom Velphoro?
For practical information about using Velphoro, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Velphoro naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
All patients were on dialysis and received either Velphoro or another phosphate binder, sevelamer, for 6 months. 
Vsi bolniki so potrebovali dializo in so 6 mesecev prejemali bodisi zdravilo Velphoro ali drug fosfatni vezalec, sevelamer.
The active substance in this medicine is sucroferric oxyhydroxide (also known as mixture of polynuclear iron(III)-oxyhydroxide, sucrose (sugar) and starches). 
Zdravilna učinkovina v zdravilu je železov(III) oksihidroksid saharozni kompleks (znan tudi kot mešanica polinuklearnega železovega(III) oksihidroksida, saharoze (sladkorja) in škroba).
Velphoro is a medicine used to control blood-phosphate levels in adults with long-term kidney disease who are undergoing haemodialysis or peritoneal dialysis to remove waste products from the blood. 
Velphoro je zdravilo, ki se uporablja za uravnavanje ravni fosfatov v krvi pri odraslih z dolgotrajno boleznijo ledvic, ki potrebujejo hemodializo ali peritonealno dializo za odstranjevanje odpadnih snovi iz krvi.
Velphoro must not be used in patients with iron accumulation disorders such as haemochromatosis. 
Zdravilo Velphoro se ne sme uporabljati pri bolnikih z motnjami, pri katerih se kopiči železo, kot je hemokromatoza.
Velphoro was as effective as sevelamer in reducing patients' blood-phosphate levels and maintaining this effect. 
Zdravilo Velphoro je bilo pri zniževanju ravni fosfatov v krvi bolnikov in ohranjanju tega učinka enako učinkovito kot sevelamer.
The active substance in Velphoro, sucroferric oxyhydroxide, is a phosphate binder. 
Zdravilna učinkovina v zdravilu Velphoro, železov(III) oksihidroksid saharozni kompleks, je fosfatni vezalec.
Velphoro sucroferric oxyhydroxide 
Velphoro železov(III) oksihidroksid saharozni kompleks
How is Velphoro used? 
Kako se zdravilo Velphoro uporablja?
How does Velphoro work? 
Kako zdravilo Velphoro deluje?
Patients should keep to their prescribed low-phosphate diets. 
Največji odmerek je 3 000 mg (6 tablet) na dan. Bolniki se morajo držati predpisane diete z majhnim vnosom fosfatov.
The average half-life is of about 1.5 hours. 
Povprečna razpolovna doba je približno 1,5 ure.
The disease progresses gradually so you may not feel any symptoms at first. 
Bolezen napreduje postopno tako, da sprva morda ne opazite nobenih simptomov.
• Some medic may come out - this is normal. 
• Nekaj zdravila lahko izteče ven - to je normalno.
You will hear and feel a click at the end. 
• Na koncu boste slišali in čutili klik.
You will hear a “click” (see picture). 
Pri tem boste slišali “klik” (glejte sliko).
The results for these subjects were not different from the results in the study as a whole. 
Rezultati teh preiskovank se niso razlikovali od celokupnih rezultatov študije.
• Do not share your medication with others. 
• Ne delite svojega zdravila z drugimi.
Date of latest renewal: 24.04.2011 
Datum zadnjega podaljšanja: 24.04.2011
Never inject more than one dose in the same day. 
Nikoli si ne injicirajte več kot en odmerek v enem dnevu.
This means that it is essentially “sodium-free”. 
To pomeni, da je v bistvu „brez natrija“.
• Let it sit for about one minute until the medicine is completely mixed. 
• Pustite ga ležati približno eno minuto, dokler se zdravilo popolnoma ne zmeša.
Please read the information in these boxes carefully - they contain important information for you. 
Prosimo vas, da skrbno preberete besedila v takšnih okvirčkih - vsebujejo za vas pomembne informacije.
• loss of appetite, 
• izguba apetita,
If you feel dizzy, do not drive or operate any machines until you feel better. 
Če ste omotični, ne vozite ali upravljajte strojev, dokler se ne počutite bolje.
DATE OF REVISION OF THE TEXT 
10 DATUM ZADNJE REVIZIJE BESEDILA
Use each needle only once. 
Vsako iglo uporabite samo enkrat.
Due to the differences in bone physiology in rats and humans, the clinical relevance of these findings is probably minor. 
Zaradi razlik v fiziologiji kosti med podganami in človekom, je klinični pomen teh odkritij verjetno manjši.
Cartridge: Glass Type I. 
Vložek: steklo tipa I.
DK-4000 Roskilde Denmark 
DK-4000 Roskilde Danska
Until further clinical data becomes available the recommended treatment time of 24 months should not be exceeded. 
Dokler ni na voljo dodatnih kliničnih podatkov, 24-mesečnega priporočenega trajanja zdravljenja ne smemo preseči.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 24.04.2006 
9 DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 24.04.2006
To prevent one or more new vertebral fractures, 48 women had to be treated for a median of 18 months for the total population. 
Za preprečitev enega ali več novih vretenčnih zlomov v celotni populaciji je bilo treba 48 žensk zdraviti z mediano trajanja 18 mesecev.
Keep using Preotact for as long as your doctor prescribes it for you - normally no longer than 24 months. 
Zdravilo Preotact uporabljajte tako dolgo, kakor vam ga predpisuje zdravnik - običajno ne dlje kot 24 mesecev.
The safety and efficacy of Preotact in patients under 18 years have not been studied. 
Varnost in učinkovitost zdravila Preotact pri bolnikih, mlajših od 18 let, ni raziskana.
Due to the relatively short duration of the pharmacological activity of Preotact further measures should not be necessary. 
Zaradi relativno kratkega trajanje farmakološke aktivnosti zdravila Preotact dodatni ukrepi niso potrebni.
• Do not use this medicine if it has not been stored correctly, even if it is not used up. 
• Ne uporabljajte tega zdravila, če ni bilo pravilno shranjeno, čeprav še ni porabljeno.
Do not push it back until you are instructed to do so in this leaflet. 
Ne pritiskajte ga nazaj, dokler vam tega ne svetujejo navodila v tem priročniku.
MARKETING AUTHORISATION NUMBER(S) EU/1/06/339/003 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/06/339/003
No differences in Preotact pharmacokinetics were detected with regard to age (range 47-88 years). 
Niso odkrili razlik v farmakokinetiki zdravila Preotact glede na starost (obseg 47-88 let).
If you forget to take Preotact (or cannot take Preotact at your usual time), take it as soon as possible on that day. 
Če pozabite uporabiti zdravilo Preotact (ali zdravila Preotact ne morete uporabiti ob običajni uri), ga uporabite čimprej na tisti dan.
Preotact should not be used in children or adolescents under 18 years old. 
Zdravilo Preotact se ne sme uporabljati pri otrocih in mladostnikih mlajših od 18 let.
Interindividual variability in systemic clearance is about 15%. 
Interindividualna variabilnost sistemskega očistka je približno 15%.
Consequently, no interaction with other medicinal products would be anticipated and no specific drug-drug interactions studies were performed. 
Zato se ne pričakuje interakcij z drugimi zdravili, niti niso bile opravljene specifične študije interakcij z drugimi zdravili.
Your doctor may advise you to take supplementary calcium and vitamin D. Your doctor will tell you how much you should take each day. 
Zdravnik vam bo morda svetoval, da jemljete dopolnila kalcija in vitamina D. Zdravnik vam bo povedal, kakšen odmerek morate vzeti dnevno.
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, any updated RMP should be submitted at the same time as the following Periodic Safety Update Report (PSUR). 
V skladu s smernico CHMP o sistemih za obvladovanje tveganja za zdravila za uporabo v humani medicini mora biti posodobljen RMP predložen hkrati z naslednjim rednim posodobljenim poročilom o varnosti zdravila (PSUR).
The steps you have to go through for each of the 14 injections: 
Za vsako od 14 injekcij morate opraviti naslednje korake:
It is especially common in women after the menopause. 
Zlasti pogosta je pri ženskah po menopavzi.
Caution should be exercised in 
Previdnost je potrebna pri
Osteoporosis is a disease that causes bones to become thin and fragile. 
Osteoporoza je bolezen, zaradi katere postanejo kosti tanke in krhke.
• if you have high levels of alkaline phosphatase (an enzyme produced by the organism; may signal certain medical conditions, related to bones and liver); 
• če imate visoke ravni alkalne fosfataze(encim, ki ga proizvaja organizem; lahko signalizira določena medicinska stanja v povezavi s kostmi in jetri);
The dose counter has now decreased by one. 
Števec odmerkov se je sedaj zmanjšal za eno enoto.
• Check that the medicine is clear. 
• Preverite, če je zdravilo bistro.
• pain in arms and legs (extremities), 
• bolečine v rokah in nogah (okončinah),
Stopper (center and end): Bromobutyl rubber, grey. 
Zamašek (osrednji in končni): bromobutilna guma, siva.
The hypercalcemia was transient and was reported most frequently in the first 3 months of treatment. 
Hiperkalciemija je bila prehodna in najpogosteje poročana v prvih 3 mesecih zdravljenja.
• fast or irregular heart beats, 
• hiter ali nepravilen srčni utrip,
Furthermore, parathyroid hormone is not protein bound and has a low volume of distribution. 
Poleg tega se obščitnični hormon ne veže na beljakovine in ima majhen volumen porazdelitve.
Each pen should be used by only one patient. 
Isti peresnik sme uporabljati samo en bolnik.
• Throw away the needle as you have been instructed by your doctor or nurse 
• Zavrzite iglo, kot vam je naročil vaš zdravnik ali medicinska sestra.
It is unknown whether recombinant human parathyroid hormone is excreted in the milk of lactating animals. 
Ni znano, ali se rekombinantni človeški obščitnični hormon izloča v materinem mleku živali, ki dojijo.